Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters

Authors

• Daniel R. Ruge, BioSentinel Pharmaceuticals
• F. Mark Dunning, BioSentinel Pharmaceuticals
• Timothy M. Piazza, University of Wisconsin–Madison
• Brian E. Molles, US Army Medical Research Institute of Chemical Defense (USAMRICD)
• Michael Adler, US Army Medical Research Institute of Chemical Defense (USAMRICD)
• Füsûn N. Zeytin, BioSentinel Pharmaceuticals
• Ward C. Tucker, BioSentinel PharmaceuticalsFollow

Document Type

Article

Date of this Version

2011

Comments

Published in Analytical Biochemistry, 411, (2011), 200–209

Abstract

Methods that do not require animal sacrifice to detect botulinum neurotoxins (BoNTs) are critical for BoNT antagonist discovery and the advancement of quantitative assays for biodefense and pharmaceutical applications. Here we describe the development and optimization of fluorogenic reporters that detect the proteolytic activity of BoNT/A, B, D, E, F, and G serotypes in real time with femtomolar to picomolar sensitivity. Notably, the reporters can detect femtomolar concentrations of BoNT/A in 4 h and BoNT/E in 20 h, sensitivity that equals that of animal-based methods. The reporters can be used to determine the specific activity of BoNT preparations with intra- and inter-assay coefficients of variation of approximately 10%. Finally, we find that the greater sensitivity of our reporters compared with those used in other commercially available assays makes the former attractive candidates for high-throughput screening of BoNT antagonists.